Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01405508 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT01405508 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 105 participants.
The verdict
NCT01405508, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, 4-arm, randomized, parallel-group study to evaluate safety and tolerability of Brivaracetam Intravenous (BRV iv) as adjunctive treatment for adults with epilepsy according to an initiation or a conversion scheme, during repeated dosing (100 mg/administration twice daily for 4.5 days).
Interventions
- OTHER Placebo
- DRUG Brivaracetam tablets
- DRUG Brivaracetam bolus
- DRUG Brivaracetam infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01405508
The ClinicalTrials.gov registry entry for NCT01405508 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01405508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01405508 about?
NCT01405508 is a clinical study titled "Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy". This is a multicenter, open-label, 4-arm, randomized, parallel-group study to evaluate safety and tolerability of Brivaracetam Intravenous (BRV iv) as adjunctive treatment for adults with epilepsy according to an initiation or a conversion scheme, during repeated dosing (100 mg/administration twice ...
What is the current status of trial NCT01405508?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2011-08. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01405508?
The interventions under investigation include: Placebo (OTHER), Brivaracetam tablets (DRUG), Brivaracetam bolus (DRUG), Brivaracetam infusion (DRUG).
Who is sponsoring clinical trial NCT01405508?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.